In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Nippon Shinyaku Co. Ltd.

www.nippon-shinyaku.co.jp

Latest From Nippon Shinyaku Co. Ltd.

Bookmark
  • News

Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements

By Michael Cipriano and Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
Bookmark
  • Analysis

Legal Challenge To First Japan Rituxan Biosimilar Dismissed

By Ian Haydock

First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.

Japan Biosimilars
Bookmark
  • Analysis

Missed BEAT Removes Tough Sell For United Therapeutics

By Eleanor Malone

The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing a therapy that was already facing an uphill battle for potentially meager returns.

Clinical Trials Research & Development
Bookmark
  • News

Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T

By Ian Haydock

Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.

Japan Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Nippon Shinyaku Co. Ltd.
  • Senior Management
  • Shigenobu Maekawa, Pres.
    Taro Sakurai, Gen. Mgr., Fin. & Accounting
    Akira Matsuura, Gen. Mgr., R&D
  • Contact Info
  • Nippon Shinyaku Co. Ltd.
    Phone: (81) 75 321 1111
    14 Nishinosho Monguchi-cho, Kisshoin
    Minami-ku
    Kyoto, 601-8550
    Japan
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By